Prasad Rajendra, Banerjee Atanu, Shah Abdul Haseeb
Institute of Integrative Sciences and Health and Institute of Biotechnology, Amity University Haryana, Amity Education Valley, Gurgaon, India
School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
Essays Biochem. 2017 Mar 3;61(1):157-166. doi: 10.1042/EBC20160067. Print 2017 Feb 28.
The evolution of antifungal resistance among fungal pathogens has rendered the limited arsenal of antifungal drugs futile. Considering the recent rise in the number of nosocomial fungal infections in immunocompromised patients, the emerging clinical multidrug resistance (MDR) has become a matter of grave concern for medical professionals. Despite advances in therapeutic interventions, it has not yet been possible to devise convincing strategies to combat antifungal resistance. Comprehensive understanding of the molecular mechanisms of antifungal resistance is essential for identification of novel targets that do not promote or delay emergence of drug resistance. The present study discusses features and limitations of the currently available antifungals, mechanisms of antifungal resistance and highlights the emerging therapeutic strategies that could be deployed to combat MDR.
真菌病原体中抗真菌耐药性的演变已使有限的抗真菌药物武器库变得无用。考虑到免疫功能低下患者医院内真菌感染数量最近有所增加，新出现的临床多重耐药性（MDR）已成为医学专业人员严重关切的问题。尽管治疗干预取得了进展，但尚未能够设计出令人信服的策略来对抗抗真菌耐药性。对抗真菌耐药性分子机制的全面理解对于识别不会促进或延缓耐药性出现的新靶点至关重要。本研究讨论了目前可用抗真菌药物的特点和局限性、抗真菌耐药性机制，并强调了可用于对抗MDR的新出现的治疗策略。
